Adaptimmune draws investor buzz, fourth cancer trial launched
This article was originally published in Scrip
UK biotechnology firm Adaptimmue's steadily growing number of clinical trials involving its early-stage, cancer-targeting, gene-engineered T-cell receptor technology is acting as honey to potential licensees, the company says.
You may also be interested in...
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.